About x4 pharmaceuticals inc - XFOR
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
XFOR At a Glance
X4 Pharmaceuticals, Inc.
61 North Beacon Street
Boston, Massachusetts 02134
| Phone | 1-857-529-8300 | Revenue | 35.11M | |
| Industry | Biotechnology | Net Income | -79,199,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1,273.211% | |
| Fiscal Year-end | 12 / 2026 | Employees | 45 | |
| View SEC Filings |
XFOR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.818 |
| Price to Book Ratio | 1.952 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.086 |
| Enterprise Value to Sales | -0.209 |
| Total Debt to Enterprise Value | -10.523 |
XFOR Efficiency
| Revenue/Employee | 780,288.889 |
| Income Per Employee | -1,759,977.778 |
| Receivables Turnover | 61.279 |
| Total Asset Turnover | 0.161 |
XFOR Liquidity
| Current Ratio | 10.148 |
| Quick Ratio | 9.974 |
| Cash Ratio | 9.854 |
XFOR Profitability
| Gross Margin | 82.18 |
| Operating Margin | -247.438 |
| Pretax Margin | -225.438 |
| Net Margin | -225.555 |
| Return on Assets | -36.254 |
| Return on Equity | -75.992 |
| Return on Total Capital | -30.048 |
| Return on Invested Capital | -43.809 |
XFOR Capital Structure
| Total Debt to Total Equity | 41.486 |
| Total Debt to Total Capital | 29.322 |
| Total Debt to Total Assets | 26.608 |
| Long-Term Debt to Equity | 40.953 |
| Long-Term Debt to Total Capital | 28.945 |